Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?

Nabiha Huq Saifee, Peter J. Krause, Yanyun Wu

Research output: Contribution to journalComment/debatepeer-review

14 Scopus citations


Babesiosis is a potentially life-threatening illness caused by intraerythrocytic protozoan parasites of the genus Babesia that are transmitted most commonly by Ixodes ticks, and rarely from blood transfusion or congenitally. Clinical presentations of babesiosis include asymptomatic infection, mild to moderate disease, or severe disease. Antibiotics such as atovaquone plus azithromycin or clindamycin and quinine can be used effectively to treat this disease in most cases, however in high risk populations, the mortality rate can be as high as 20% despite therapy. Therapeutic exchange transfusion has been used in severe babesiosis and is of apparent therapeutic benefit. It is not entirely clear through what mechanism therapeutic exchange transfusion may help patients. Data suggests that in addition to parasite load reduction, it is possible that therapeutic exchange transfusion removes toxins generated by babesia infection. There are many remaining questions that need to be addressed regarding exchange transfusion for babesiosis. J. Clin. Apheresis 31:454–458, 2016.

Original languageEnglish (US)
Pages (from-to)454-458
Number of pages5
JournalJournal of Clinical Apheresis
Issue number5
StatePublished - Oct 1 2016
Externally publishedYes


  • Babesiosis
  • RBC exchange

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?'. Together they form a unique fingerprint.

Cite this